JAMP-BICALUTAMIDE 50 MG
BICALUTAMIDE : 50 MG · DIN 02357216 · JAMP PHARMA CORPORATION
Health Canada status: MARKETED
What is JAMP-BICALUTAMIDE?
JAMP-BICALUTAMIDE 50 MG contains BICALUTAMIDE : 50 MG. It is listed in the Health Canada Drug Product Database under DIN 02357216, held by JAMP PHARMA CORPORATION, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 21-May-2026. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is JAMP-BICALUTAMIDE used for?
Combination therapy with LHRH analogue or surgical castration for metastatic (Stage D2) prostate cancer. (Max 200 chars)
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02357216 |
|---|---|
| Brand name | JAMP-BICALUTAMIDE |
| Generic / active ingredient | BICALUTAMIDE : 50 MG |
| Manufacturer | JAMP PHARMA CORPORATION |
| Strength | 50 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | L02BB03 BICALUTAMIDE |
| AHFS class | 10:00.00 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 21-May-2026 |
| Original market date | 2010-10-21 00:00:00 |
How is it administered?
50 mg tablet once daily with or without food, started at the same time as LHRH analogue treatment or after surgical castration.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly specified in the provided text (referred to "STORAGE AND STABILITY" section which is not fully detailed).
How is it supplied?
Not explicitly specified in the provided text (mentions "Dosage Forms, Composition and Packaging section" but details are truncated).
Contraindications
Hypersensitivity to drug; localized prostate cancer undergoing watchful waiting; women; children.
Warnings and precautions
Qualified professional use only. Risk of hepatic failure, interstitial lung disease, cardiovascular disease, QT prolongation, and decreased bone density. 150 mg dose NOT to be used.
Is BICALUTAMIDE in shortage in Canada?
A Canadian shortage report is on file for this molecule: Resolved — reported by SANIS HEALTH INC, last seen 05 May 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code L02BB03 BICALUTAMIDE. 6 of 25 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| ACH-BICALUTAMIDE | 50 MG | TABLET | ACCORD HEALTHCARE INC | MARKETED | DIN 02325985 |
| BICALUTAMIDE | 50 MG | TABLET | SANIS HEALTH INC | MARKETED | DIN 02519178 |
| PMS-BICALUTAMIDE | 50 MG | TABLET | PHARMASCIENCE INC | MARKETED | DIN 02275589 |
| PRO-BICALUTAMIDE - 50 | 50 MG | TABLET | PRO DOC LIMITEE | MARKETED | DIN 02311038 |
| TEVA-BICALUTAMIDE | 50 MG | TABLET | TEVA CANADA LIMITED | MARKETED | DIN 02270226 |
| ACCEL-BICALUTAMIDE TABLETS USP | 50 MG | TABLET | ACCEL PHARMA INC | CANCELLED PRE MARKET | DIN 02400731 |
| ACT BICALUTAMIDE | 50 MG | TABLET | ACTAVIS PHARMA COMPANY | CANCELLED POST MARKET | DIN 02274337 |
| AG-BICALUTAMIDE | 50 MG | TABLET | ANGITA PHARMA INC. | CANCELLED PRE MARKET | DIN 02374412 |
| APO-BICALUTAMIDE | 50 MG | TABLET | APOTEX INC | DORMANT | DIN 02296063 |
| AVA-BICALUTAMIDE | 50 MG | TABLET | AVANSTRA INC | CANCELLED POST MARKET | DIN 02360993 |
Who else supplies BICALUTAMIDE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. BICALUTAMIDE appears in 158 registered pack listings across 14 markets, published on 11 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.